Related Experiment Video

Updated: Jul 10, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Fibrinolytic agents for the management of ST-segment elevation myocardial infarction

Daniel E Hilleman1, James P Tsikouris, A Allen Seals

  • 1Creighton University Cardiac Center, 2500 California Plaza, 3006 Webster Street, Omaha, NE 68131, USA. hilleman@creighton.edu

Pharmacotherapy
|October 30, 2007
PubMed

Insights

Rapid reperfusion is crucial for ST-elevation myocardial infarction (STEMI) patients. Fibrinolytic agents, like alteplase, reteplase, and tenecteplase, are key pharmacologic treatments to restore blood flow and reduce mortality.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • ST-segment elevation myocardial infarction (STEMI) requires rapid reperfusion.
  • Pharmacologic reperfusion using fibrinolytic agents is recommended by ACC-AHA guidelines.

Purpose of the Study:

  • To review fibrinolytic agents for STEMI management.
  • To highlight the importance of guideline adherence and agent knowledge for clinicians.

Main Methods:

  • Review of ACC-AHA guidelines for STEMI management.
  • Discussion of four approved fibrinolytic agents: streptokinase, alteplase, reteplase, and tenecteplase.
  • Comparison of administration methods (infusion vs. bolus) and dosing strategies.

Main Results:

  • Fibrinolytic agents restore blood flow within 12 hours of symptom onset.
  • Clinical trials show reduced mortality rates with fibrinolytic therapy.
  • Reteplase and tenecteplase offer bolus administration advantages over alteplase infusion.

Conclusions:

  • Fibrinolytic agents are essential for STEMI reperfusion therapy.
  • Understanding agent-specific properties (dosing, administration) is vital for optimal patient outcomes.
  • Physicians and pharmacists must adhere to guidelines for informed treatment decisions.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.